Does discontinuation of β-blockers beyond 1 year after AMI increase the risk of death or readmission for ACS in revascularized patients without heart failure?
Discontinuing beta-blockers beyond 1 year after AMI in revascularized patients without heart failure may increase the risk of death or ACS readmission.
In routine care of patients without heart failure, revascularized and optimally treated after AMI, discontinuation of β-blockers beyond 1 year after AMI was associated with an increased risk of death or readmission for ACS, while statistical significance was not reached for the association with all-cause mortality. A contemporary randomized clinical trial is needed to precise the role of β-blockers in the long-term treatment after AMI.
Neumann et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: